


Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. **(currently amended)** A compound in the form of an enantiomer or in the form of a mixture of enantiomers, having the formula (I)



in which R represents ~~a halogen atom~~ or a (C₃-C₆)cycloalkyl group or a phenyl group substituted by one or more groups chosen from a halogen atom, or a (C₁-C₆)alkyl, (C₁-C₆)alkoxy, nitro, amino, (C₁-C₃)dialkylamino, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, acetyl or methylenedioxy group, or a piperidinyl, or morpholin-4-yl, or pyrrolidin-1-yl, or azetidin-1-yl, or azepin-1-yl, or pyridinyl, or quinolinyl, or thienyl, or pyrazinyl, or furyl, or benzofuryl, or benzothienyl, or indolyl, or pyrimidinyl, or isoxazolyl, or phenoxazinyl, or phenoxathienyl, or dibenzothienyl, or dibenzofuryl, or pyrrolyl, or naphthyl group, where each of these groups may optionally be substituted by one or more groups chosen from halogen atoms, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxy, amino, (C₁-C₃)dialkylamino or (C₃-C₈)cycloalkylamino groups, and where, of the two carbon-carbon bonds represented by ----, one is a single bond and the other is either a single bond or a double bond, or a salt thereof; ~~and with the exception of following compounds:~~

~~5-(2-bromopyridin-5-yl)-1-azabicyclo[2.3.1]octane;~~

~~5-(2-chloropyridin-5-yl)-1-azabicyclo[2.3.1]octane;~~

~~5-(2-fluoropyridin-5-yl)-1-azabicyclo[2.3.1]octane.~~

2. **(currently amended)** The compound according to Claim 1 wherein R ~~either~~ represents a ~~halogen atom or~~ a phenyl group substituted by one or more groups chosen from halogen atoms and (C₁-C₆)alkyl, (C₁-C₆)alkoxy, nitro, amino, trifluoromethyl, cyano, hydroxy, acetyl or methylenedioxy groups, or represents a pyridinyl group or a thienyl group or an indolyl group or a pyrimidinyl group optionally substituted by one or more (C₁-C₆)alkoxy groups.
3. **(previously presented)** A method for the treatment of a disorder selected from the group consisting of detrimental memory and attentional changes, Alzheimer's disease, Parkinson's disease, Tourette's syndrome and withdrawal from tobacco, which comprises administering to a patient in need of said treatment an effective amount of a compound according to Claim 1.
4. **(previously presented)** Pharmaceutical composition which comprises a compound according to Claim 1, together with an excipient.
5. **(previously presented)** A method for the treatment of a disorder selected from the group consisting of detrimental memory and attentional changes, Alzheimer's disease, Parkinson's disease, Tourette's syndrome and withdrawal from tobacco, which comprises administering to a patient in need of said treatment an effective amount of a compound according to Claim 2.
6. **(original)** Pharmaceutical composition which comprises a compound according to Claim 2, together with an excipient.
7. **(new)** A compound selected from the group consisting of:
5-(6-bromo-pyridin-3-yl)-1-aza-bicyclo[3.2.1]oct-2-ene; and
5-(6-bromo-pyridin-3-yl)-1-aza-bicyclo[3.2.1]oct-3-ene; or a salt thereof.

8 **(new)** A pharmaceutical composition which comprises a compound according to Claim 7, or a pharmaceutically acceptable salt thereof together with an excipient.

9. **(new)** A method for the treatment of a disorder selected from the group consisting of detrimental memory and attentional changes, Alzheimer's disease, Parkinson's disease, Tourette's syndrome and withdrawal from tobacco, which comprises administering to a patient in need of said treatment an effective amount of a compound according to Claim 7.